Abstract
Angiogenesis inhibitors (AIs) such as bevacizumab (BEV) and ramucirumab (RAM) plays an important role in the treatment of metastatic colorectal cancer (mCRC). Although BEV blocks circulating VEGF-A, RAM is an anti-VEGF receptor 2 antibody which prevents ligands (VEGF-A, C, and D) binding. AIs can cause renal adverse events (AEs) including proteinuria and nephrotic syndrome, but little is known about whether previous therapy affects renal AEs. The purpose of this study is to evaluate the association between BEV-induced proteinuria and history of RAM in mCRC patients (pts).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
